Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs)

Inclusion Criteria: * Subject must be ≥ 18 years of age or legal age at the time of enrollment. * Chronic venous insufficiency confirmed by ultrasound within previous 12 months. * Active ulceration (CEAP classification of C6) * Ulcer duration: ≥ 2 month but not greater than 24 months - non healing VLU with conservative treatment. * Ulcer size ≥ 2cm2 ≤ 50cm2 * Leg circumferences within the following range:Ankle - 12 to 44cm;Calf - 22 to 60cm; Below knee - 22 to 68cm Exclusion Criteria: * Target ulcer or any other ulcer on the study limb involves exposure of tendon, muscle, or bone. * Greater than 3 separate full thickness ulcers on the study limb * Target ulcer is of non-venous etiology (sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma, malignancy). * Treatment of the target ulcer with living cellular therapy within 30 days of the time of enrollment. * History of an acute deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last 3 months. * Either the dorsalis pedis (DP) or posterior tibial (PT) systolic pressure \< 80mmHg for diabetic patients or \< 60mmHg for non-diabetic patients on study limb or transcutaneous partial pressure oxygen (Tcp02) ≤ 30mmHg or great toe systolic pressure ≤ 40mmHg. * Acute thrombophlebitis. * History of pulmonary edema or decompensated congestive heart failure. * Currently has an active infection of the skin such as cellulitis requiring antibiotics. * History of cancer within the last 5 years with the exception of treated non-melanoma skin cancer or cervical carcinoma in situ. * Poorly controlled diabetes with a Hemoglobin A1c (HbA1c) value of \>12%. * Changes to medications that affect edema within the last 30 days * Need for current and ongoing therapy with corticosteroids (exception for continued low dose usage) or cytotoxic drugs or the current use of Daflon 500. * Currently pregnant or trying to become pregnant. * Inability or unwillingness to participate in all aspects of study protocol. * Currently participating in another clinical trial.